GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (STU:AB3A) » Definitions » Cyclically Adjusted PS Ratio

Sarepta Therapeutics (STU:AB3A) Cyclically Adjusted PS Ratio : 16.08 (As of Jun. 06, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sarepta Therapeutics Cyclically Adjusted PS Ratio?

As of today (2024-06-06), Sarepta Therapeutics's current share price is €109.85. Sarepta Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €6.83. Sarepta Therapeutics's Cyclically Adjusted PS Ratio for today is 16.08.

The historical rank and industry rank for Sarepta Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:AB3A' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 10.07   Med: 25.63   Max: 98.48
Current: 16.2

During the past years, Sarepta Therapeutics's highest Cyclically Adjusted PS Ratio was 98.48. The lowest was 10.07. And the median was 25.63.

STU:AB3A's Cyclically Adjusted PS Ratio is ranked worse than
79.56% of 504 companies
in the Biotechnology industry
Industry Median: 5.525 vs STU:AB3A: 16.20

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sarepta Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2024 was €3.838. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €6.83 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sarepta Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Sarepta Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Cyclically Adjusted PS Ratio Chart

Sarepta Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.29 58.37 23.38 25.31 14.17

Sarepta Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.96 19.36 18.98 14.17 17.51

Competitive Comparison of Sarepta Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Sarepta Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Cyclically Adjusted PS Ratio falls into.



Sarepta Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sarepta Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=109.85/6.83
=16.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Sarepta Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.838/131.7762*131.7762
=3.838

Current CPI (Mar. 2024) = 131.7762.

Sarepta Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.048 100.560 0.063
201409 0.020 100.428 0.026
201412 0.001 99.070 0.001
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.026 99.792 0.034
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.094 101.863 0.122
201703 0.273 102.862 0.350
201706 0.567 103.349 0.723
201709 0.627 104.136 0.793
201712 0.759 104.011 0.962
201803 0.811 105.290 1.015
201806 0.961 106.317 1.191
201809 1.016 106.507 1.257
201812 1.081 105.998 1.344
201903 1.074 107.251 1.320
201906 1.133 108.070 1.382
201909 1.212 108.329 1.474
201912 1.208 108.420 1.468
202003 1.346 108.902 1.629
202006 1.564 108.767 1.895
202009 1.557 109.815 1.868
202012 1.512 109.897 1.813
202103 1.553 111.754 1.831
202106 1.708 114.631 1.963
202109 2.015 115.734 2.294
202112 2.074 117.630 2.323
202203 2.194 121.301 2.383
202206 2.524 125.017 2.660
202209 2.654 125.227 2.793
202212 2.777 125.222 2.922
202303 2.685 127.348 2.778
202306 2.717 128.729 2.781
202309 3.498 129.860 3.550
202312 3.506 129.419 3.570
202403 3.838 131.776 3.838

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sarepta Therapeutics  (STU:AB3A) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sarepta Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sarepta Therapeutics (STU:AB3A) Business Description

Traded in Other Exchanges
Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Sarepta Therapeutics (STU:AB3A) Headlines

No Headlines